Login
← Go Back
Marksans Pharma
MARKSANS · Pharma > Pharmaceuticals & Drugs · Chairman: Mark Saldanha · MD: Mark Saldanha · Listing date: Jan. 22, 2002 · Employees: 1138 · Mumbai · http://www.marksanspharma.com
Stock Price vs Company Growth
1d
2.5%
1w
7.8%
1m
1.5%
3m
48.6%
6m
86.9%
1y
151.9%
5y
82.6%
10y
17.3%
all
20.6%
🤔 How to analyze this graph?
Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price
₹ 294 2.5%
186
328
Company Overview
Sales
2,268 Cr
Growth: 16.6%
Profit after Tax
334 Cr
Growth: 6.4%
Mid Cap
13,334 Cr
P/E: 39.8x
Industry P/E: 41.5x
Fundamentals
Sales (Cr) ₹ 2,268
Growth 16.6%
EBITDA 21.4%
P/S 5.9x
Dividend 0.6%
P/E 39.8x
Book Value ₹ 47.5
PEG Ratio 2.3x
ROE 16.5%
P/B 6.0x
Shareholding Pattern
Institutions
Promoters
Mark Saldanha
48.25 %
Others
Mukul Mahavir Prasad Agrawal
1.47 %
Increase    Decrease    No change
Company Profile Detailed
Marksans Pharma, incorporated in 1992, was a wholly-owned subsidiary of Glenmark Pharmaceuticals. It became a separate entity in March 2003 and the name was changed to Marksans Pharma in 2005.Currently the company has presence in Active Pharmaceuticals Ingredients (APIs), formulations and biopharmaceuticals. It is also actively engaged in research and development and offers contract research and manufacturing services (CRAMS) to global pharmaceutical companies.
Belongs to (6 Indices) view more
Investors (38)
wasatch....
kaushik5
ashish.k...
Followers (7)
akash2
karan3
sachin3